Ranbaxy in bid to make generic version of Nexium

Share this article:
AstraZeneca said Tuesday that India's biggest drug maker, Ranbaxy Laboratories, has filed an Abbreviated New Drug Application (ANDA) with the FDA to make its own version of the ulcer treatment Nexium (esomeprazole magnesium delayed-release capsules).
Nexium is AstraZeneca's top seller, bringing in $3.8 billion in revenue in 2004.
AstraZeneca is already fighting a challenge to Nexium from Indian generic drug maker Dr. Reddy's Laboratories.
AstraZeneca has 45 days within which to commence a patent infringement lawsuit against Ranbaxy that would automatically stay, or bar, the FDA from approving Ranbaxy's ANDA for 30 months or until a court decision, whichever comes first.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.